Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Quince Therapeutics, Inc. (QNCX) since 2019 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Quince Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1662774.
Total stock buying since 2019: $11,856,614.
Total stock sales since 2019: $28,069,409.
Total stock option exercises since 2019: $928,740.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2024 | 241,811 | $162,781 | 0 | $0 | 56,061 | $30,833 |
| 2023 | 748,198 | $908,792 | 1,871 | $1,833 | 0 | $0 |
| 2022 | 0 | $0 | 10,800 | $30,920 | 0 | $0 |
| 2021 | 100,763 | $3,480,486 | 222,774 | $11,924,536 | 193,963 | $690,880 |
| 2020 | 111,503 | $5,454,059 | 410,000 | $16,112,120 | 71,761 | $207,027 |
| 2019 | 99,790 | $1,850,496 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2024-08 | 241,811 | $162,781 | 0 | $0 | 0 | $0 |
| 2024-06 | 0 | $0 | 0 | $0 | 56,061 | $30,833 |
| 2023-12 | 139,628 | $140,660 | 0 | $0 | 0 | $0 |
| 2023-11 | 28,756 | $27,030 | 0 | $0 | 0 | $0 |
| 2023-08 | 579,814 | $741,102 | 0 | $0 | 0 | $0 |
| 2023-03 | 0 | $0 | 1,871 | $1,833 | 0 | $0 |
| 2022-06 | 0 | $0 | 10,800 | $30,920 | 0 | $0 |
| 2021-11 | 763 | $10,987 | 0 | $0 | 90,000 | $94,500 |
| 2021-10 | 0 | $0 | 5,963 | $577,785 | 5,963 | $289,220 |
| 2021-08 | 0 | $0 | 38,000 | $3,699,396 | 68,000 | $240,260 |
| 2021-07 | 0 | $0 | 58,261 | $3,172,624 | 30,000 | $66,900 |
| 2021-06 | 0 | $0 | 550 | $30,391 | 0 | $0 |
| 2021-05 | 0 | $0 | 30,000 | $1,058,850 | 0 | $0 |
| 2021-03 | 100,000 | $3,469,499 | 30,000 | $1,080,990 | 0 | $0 |
| 2021-02 | 0 | $0 | 60,000 | $2,304,500 | 0 | $0 |
| 2020-12 | 0 | $0 | 40,000 | $1,245,520 | 43,500 | $11,745 |
| 2020-06 | 58,165 | $2,517,796 | 370,000 | $14,866,600 | 0 | $0 |
| 2020-05 | 53,338 | $2,936,263 | 0 | $0 | 5,515 | $38,108 |
| 2020-04 | 0 | $0 | 0 | $0 | 5,515 | $38,108 |
| 2020-02 | 0 | $0 | 0 | $0 | 17,231 | $119,066 |
| 2019-08 | 7,765 | $199,960 | 0 | $0 | 0 | $0 |
| 2019-05 | 92,025 | $1,650,536 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-08-30 | Thye Dirk (CEO AND CHIEF MEDICAL OFFICER) | Buy | 77,000 | .70 | 53,900 |
| 2024-08-29 | Thye Dirk (CEO AND CHIEF MEDICAL OFFICER) | Buy | 77,500 | .69 | 53,474 |
| 2024-08-21 | Hannah Brendan (CHIEF BUSINESS OFFICER AND COO) | Buy | 30,845 | .62 | 19,123 |
| 2024-08-20 | Hannah Brendan (CHIEF BUSINESS OFFICER AND COO) | Buy | 5,924 | .60 | 3,584 |
| 2024-08-20 | Ryan Charles S. (PRESIDENT) | Buy | 48,387 | .65 | 31,451 |
| 2024-08-19 | Hannah Brendan (CHIEF BUSINESS OFFICER AND COO) | Buy | 2,155 | .58 | 1,249 |
| 2024-06-04 | Hannah Brendan (CHIEF BUSINESS OFFICER AND COO) | Option Ex | 56,061 | .55 | 30,833 |
| 2023-12-14 | Lamond David (Director) | Buy | 22,627 | 1.04 | 23,532 |
| 2023-12-13 | Lamond David (Director) | Buy | 22,627 | 1.00 | 22,627 |
| 2023-12-12 | Lamond David (Director) | Buy | 22,627 | 1.01 | 22,853 |
| 2023-12-07 | Lamond David (Director) | Buy | 19,123 | 1.01 | 19,314 |
| 2023-12-06 | Lamond David (Director) | Buy | 19,123 | 1.02 | 19,505 |
| 2023-12-05 | Lamond David (Director) | Buy | 19,123 | 1.01 | 19,314 |
| 2023-12-01 | Lamond David (Director) | Buy | 14,378 | .94 | 13,515 |
| 2023-11-30 | Lamond David (Director) | Buy | 14,378 | .90 | 12,940 |
| 2023-11-29 | Lamond David (Director) | Buy | 14,378 | .98 | 14,090 |
| 2023-08-31 | Lamond David (Director) | Buy | 41,026 | 1.32 | 54,154 |
| 2023-08-30 | Lamond David (Director) | Buy | 41,026 | 1.31 | 53,744 |
| 2023-08-17 | Lamond David (Director) | Buy | 24,766 | 1.29 | 31,948 |
| 2023-08-16 | Lamond David (Director) | Buy | 117,348 | 1.29 | 151,378 |
| 2023-08-15 | Lamond David (Director) | Buy | 107,886 | 1.32 | 142,409 |
| 2023-08-10 | Thye Dirk (Chief Executive Officer) | Buy | 88,000 | 1.26 | 110,880 |
| 2023-08-08 | Hannah Brendan (Chief Business Officer) | Buy | 71,762 | 1.22 | 87,549 |
| 2023-08-08 | Mcloughlin Margaret (Director) | Buy | 8,000 | 1.23 | 9,840 |
| 2023-08-08 | Thye Dirk (Chief Executive Officer) | Buy | 80,000 | 1.24 | 99,200 |
| 2023-03-06 | Monohon Ted (Chief Accounting Officer & VP) | Sale | 1,871 | .98 | 1,833 |
| 2022-06-06 | Mcdowell Caryn Gordon (Chief Legal & Adm. Officer) | Sale | 10,800 | 2.86 | 30,920 |
| 2021-11-18 | Lynch Casey (Chief Executive Officer) | Option Ex | 60,000 | .46 | 27,600 |
| 2021-11-16 | Lowe Christopher P. (COO & Chief Financial Officer) | Option Ex | 30,000 | 2.23 | 66,900 |
| 2021-11-12 | Dominy Stephen S. (Chief Scientific Officer) | Buy | 763 | 14.40 | 10,987 |
| 2021-10-08 | Mcloughlin Margaret (Director) | Sale | 1,000 | 88.93 | 88,930 |
| 2021-10-08 | Mcloughlin Margaret (Director) | Option Ex | 1,000 | 17.00 | 17,000 |
| 2021-10-05 | Lowe Christopher P. (COO & Chief Financial Officer) | Sale | 4,963 | 98.50 | 488,855 |
| 2021-10-05 | Lowe Christopher P. (COO & Chief Financial Officer) | Option Ex | 4,963 | 54.85 | 272,220 |
| 2021-08-17 | Lowe Christopher P. (COO & Chief Financial Officer) | Option Ex | 30,000 | 2.23 | 66,900 |
| 2021-08-16 | Mcloughlin Margaret (Director) | Sale | 6,000 | 96.62 | 579,696 |
| 2021-08-16 | Mcloughlin Margaret (Director) | Option Ex | 6,000 | 17.00 | 102,000 |
| 2021-08-16 | Lowe Christopher P. (COO & Chief Financial Officer) | Sale | 22,000 | 96.35 | 2,119,700 |
| 2021-08-16 | Lowe Christopher P. (COO & Chief Financial Officer) | Option Ex | 22,000 | 2.23 | 49,060 |
| 2021-08-10 | Detke Michael J. (Chief Medical Officer) | Sale | 10,000 | 100.00 | 1,000,000 |
| 2021-08-10 | Detke Michael J. (Chief Medical Officer) | Option Ex | 10,000 | 2.23 | 22,300 |
| 2021-07-07 | Detke Michael J. (Chief Medical Officer) | Sale | 17,400 | 55.25 | 961,350 |
| 2021-07-07 | Detke Michael J. (Chief Medical Officer) | Option Ex | 17,400 | 2.23 | 38,802 |
| 2021-07-06 | Detke Michael J. (Chief Medical Officer) | Sale | 40,861 | 54.12 | 2,211,274 |
| 2021-07-06 | Detke Michael J. (Chief Medical Officer) | Option Ex | 12,600 | 2.23 | 28,098 |
| 2021-06-28 | Mcloughlin Margaret (Director) | Sale | 550 | 55.26 | 30,391 |
| 2021-05-10 | Lynch Casey (Chief Executive Officer) | Sale | 30,000 | 35.30 | 1,058,850 |
| 2021-03-24 | Lamond David (Director) | Buy | 50,000 | 33.77 | 1,688,500 |
| 2021-03-22 | Lynch Casey (Chief Executive Officer) | Sale | 30,000 | 36.03 | 1,080,990 |
| 2021-03-04 | Lamond David (Director) | Buy | 50,000 | 35.62 | 1,780,999 |
| 2021-02-03 | Lynch Casey (Chief Executive Officer) | Sale | 20,000 | 41.85 | 837,000 |
| 2021-02-02 | Lynch Casey (Chief Executive Officer) | Sale | 20,000 | 36.38 | 727,700 |
| 2021-02-01 | Lynch Casey (Chief Executive Officer) | Sale | 20,000 | 36.99 | 739,800 |
| 2020-12-14 | Holsinger Leslie (Executive Vice President) | Sale | 40,000 | 31.14 | 1,245,520 |
| 2020-12-14 | Holsinger Leslie (Executive Vice President) | Option Ex | 40,000 | .27 | 10,800 |
| 2020-12-10 | Holsinger Leslie (Executive Vice President) | Option Ex | 3,500 | .27 | 945 |
| 2020-06-12 | Boeding Chad (Other) | Buy | 2,440 | 44.06 | 107,506 |
| 2020-06-11 | Boeding Chad (Other) | Buy | 6,600 | 44.32 | 292,512 |
| 2020-06-04 | Lamond David (Director) | Buy | 49,125 | 43.11 | 2,117,778 |
| 2020-06-03 | Pfizer Ventures (us) Llc (10% Owner) | Sale | 370,000 | 40.18 | 14,866,600 |
| 2020-05-27 | Detke Michael J. (Chief Medical Officer) | Option Ex | 5,515 | 6.91 | 38,108 |
| 2020-05-22 | Boeding Chad (Other) | Buy | 2,085 | 55.90 | 116,551 |
| 2020-05-21 | Boeding Chad (Other) | Buy | 520 | 55.80 | 29,016 |
| 2020-05-20 | Boeding Chad (Other) | Buy | 6,085 | 57.61 | 350,556 |
| 2020-05-19 | Lamond David (Director) | Buy | 39,200 | 55.31 | 2,168,073 |
| 2020-05-15 | Lamond David (Director) | Buy | 5,448 | 49.94 | 272,067 |
| 2020-04-02 | Detke Michael J. (Chief Medical Officer) | Option Ex | 5,515 | 6.91 | 38,108 |
| 2020-02-07 | Detke Michael J. (Chief Medical Officer) | Option Ex | 17,231 | 6.91 | 119,066 |
| 2019-08-21 | Boeding Chad (Other) | Buy | 2,055 | 24.87 | 51,105 |
| 2019-08-20 | Boeding Chad (Other) | Buy | 2,910 | 25.69 | 74,757 |
| 2019-08-19 | Boeding Chad (Other) | Buy | 2,100 | 26.50 | 55,639 |
| 2019-08-16 | Boeding Chad (Other) | Buy | 700 | 26.37 | 18,459 |
| 2019-05-13 | Pfizer Strategic Investment Holdings Llc (10% Owner) | Buy | 50,000 | 17.00 | 850,000 |
| 2019-05-13 | Mcloughlin Margaret (Director) | Buy | 550 | 17.00 | 9,350 |
| 2019-05-13 | Young Kevin (Director) | Buy | 30,000 | 17.00 | 510,000 |
| 2019-05-13 | Ryan Una S (Director) | Buy | 2,875 | 17.00 | 48,875 |
| 2019-05-10 | Boeding Chad (10% Owner) | Buy | 8,600 | 27.01 | 232,311 |
Insider trading activities including stock purchases, stock sales, and option exercises of QNCX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Quince Therapeutics, Inc. (symbol QNCX, CIK number 1662774) see the Securities and Exchange Commission (SEC) website.